New Study Warns of Heart and Kidney Risks Associated with the Common Pain Reliever Etoricoxib
Nikhil Prasad Fact checked by:Thailand Medical News Team Nov 01, 2024 1 day, 2 hours, 45 minutes ago
Medical News: In recent research from Saudi Arabia and Jordan, scientists have taken a closer look at the effects of etoricoxib, a widely used anti-inflammatory drug. With a growing demand for medications that relieve pain without severe side effects, etoricoxib has been a go-to choice for people dealing with chronic pain. However, researchers are now examining its safety for heart and kidney health, sparking questions about its long-term impact.
New Study Warns of Heart and Kidney Risks Associated with the Common Pain Reliever Etoricoxib
The team conducting this groundbreaking research included scientists from prominent institutions: King Abdulaziz City for Science and Technology in Riyadh, Saudi Arabia; King Abdulaziz University in Jeddah, Saudi Arabia; and Al-Balqa Applied University in Al-Salt, Jordan. This
Medical News report explores the findings, which highlight significant changes in heart and kidney tissues in experimental mice treated with etoricoxib, compared with another similar drug, celecoxib.
Etoricoxib is a selective COX-2 inhibitor, often prescribed to relieve inflammation and pain without affecting the stomach lining, unlike other nonsteroidal anti-inflammatory drugs (NSAIDs). While it’s often considered safer than older drugs, recent research suggests that etoricoxib may still carry serious risks. In this article, we dive into the study’s findings, examining what happens to the heart and kidneys with long-term use of this drug and what it could mean for patients relying on it.
Key Findings: Heart and Kidney Changes
The study, conducted on mice, involved giving doses of etoricoxib and celecoxib over a 28-day period. Mice were divided into different groups based on dosage levels, allowing researchers to observe the effects of both high and low doses. The study focused on examining tissue changes in the heart and kidneys and assessing alterations in certain gene expressions linked to inflammation and heart health.
Kidney Findings: Signs of Toxicity
The kidney analysis was eye-opening. Mice that received etoricoxib showed significant tissue changes compared to the control group. Their kidneys displayed various forms of damage, such as:
-Glomerular Changes: The glomeruli, which filter blood in the kidneys, were either atrophic (shrunken) or hypertrophic (enlarged) in the treated mice.
-Tubular Damage: There were signs of vacuolation (cellular swelling) and the flattening of cells in the tubules, which are crucial for filtering waste.
-Inflammation: Some mice also showed wider interstitial spaces, areas where fluids collect between cells, indicating inflammation and potential tissue damage.
The severity of these changes depended on the dose of etoricoxib, with higher doses resulting in more pronounced damage. Celecoxib-treated mice displayed similar effects, although to a lesser degree. These kidney issues raise c
oncerns for those with pre-existing kidney conditions, as the drug could potentially worsen such conditions over time.
Heart Findings: Disorganized Muscle Fibers
Similarly, heart tissues from the treated mice showed signs of significant changes, raising concerns about etoricoxib’s potential impact on cardiovascular health. Researchers observed:
-Disorganized Cardiac Muscle: The heart’s muscle fibers were misaligned and showed signs of degeneration, especially in high-dose groups.
-Increased Space Between Fibers: Wider spaces between heart muscle cells were also found, which could indicate weakened tissue structure and potential damage.
-Gene Expression Changes: Etoricoxib-treated hearts showed increased expression of beta-adrenergic receptors and certain enzymes involved in arachidonic acid metabolism, which are often linked to inflammation and tissue damage.
These findings point to a pattern of inflammation and structural changes in the heart, suggesting that regular use of etoricoxib might carry cardiovascular risks, especially for those with heart conditions or a history of heart disease.
Implications for Pain Management
The study’s results emphasize the need for caution when using etoricoxib, especially among patients with pre-existing heart or kidney issues. Doctors may need to weigh the risks and benefits carefully, particularly for those who require long-term use. As it stands, etoricoxib is popular due to its effectiveness in managing pain with fewer stomach-related side effects. However, the findings highlight the importance of regular monitoring, especially for patients at risk of heart or kidney complications.
Limitations and Future Directions
While the study provides compelling evidence about the potential risks of etoricoxib, it’s worth noting that it was conducted on mice. Further studies on humans are necessary to confirm these findings and better understand the drug’s long-term effects. Given the structural similarities in human and mouse kidneys and hearts, the results are concerning, but more clinical research will help determine if similar effects are seen in people.
In the meantime, patients taking etoricoxib should speak with their healthcare provider, particularly if they have concerns about heart or kidney health. Regular check-ups and monitoring can help mitigate risks, and there may be alternative medications that offer pain relief without impacting heart or kidney function.
Study Conclusions
In conclusion, the study suggests that while etoricoxib offers effective pain relief, it may come with risks that should not be ignored. The potential for kidney and heart damage, especially at higher doses, highlights the importance of informed, cautious use. This research points to a need for careful consideration by both patients and healthcare providers in choosing the right pain management strategy. Monitoring and open communication with healthcare providers remain key, particularly for those with pre-existing health issues.
The study findings were published in the peer-reviewed journal: Pharmaceuticals.
https://www.mdpi.com/1424-8247/17/11/1454
For the latest Med News, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/proton-pump-inhibitors-ppis-impact-gut-health-by-translocating-oral-microbiota
https://www.thailandmedical.news/news/med-news-pfizer-s-pregabalin-that-is-used-to-treat-anxiety-and-neuropathic-pain-linked-to-rising-drug-related-deaths
https://www.thailandmedical.news/articles/med-news
Share
Tweet
Share
